In a CSMS message posted July 9, 2025, U.S. Customs and Border Protection (CBP) announced that, effective immediately, all shipments of products regulated by the U.S. Food and Drug Administration (FDA) must be subject to FDA-review upon importation.

Imported goods are subject not only to U.S. customs laws, but also to any applicable requirements and review by partner government agencies (PGA), including the FDA, the Center for Disease Control, the Animal and Plant Health Inspection Service, Food Safety and Inspection Service, the Consumer Product Safety Commission and others that regulate imports and enforce compliance with certain health and safety regulations.  PGAs collaborate with CBP to oversee and inspect imports, ensuring that imports meet certain product specifications and requirements.  Importers of such goods are required to assign PGA Message Sets to the entry, which effectively alert the target agency of the importation.  PGAs help review entry submissions and determine whether imports are admissible.  Goods found to be in violation of PGA requirements can be subject to penalties, import refusals, and seizure by CBP.

In the past, the FDA has treated certain categories of products—cosmetics, dinnerware, radiation emitting non-medical devices, biological samples for laboratory testing, and most food items—as exempt from the PGA requirement when the shipment qualifies for de minimis treatment under Section 321 of the Tariff Act of 1930.  CBP’s Section 321 de minimis program allows duty-free entry for certain shipments imported by one person on one day not exceeding $800 in aggregate fair retail value.  (The Trump administration recently curtailed the program by excluding products of China and Hong Kong from de minimis benefits.)  Under previous guidance, CBP and PGAs could clear de minimis shipments entered through Entry Type 86 without PGA data.

In the July 9 CSMS, CBP explained that, with technological advancements, the FDA now has the capability to review and screen all electronically transmitted FDA-related imports, regardless of shipment quantity and value, and emphasized that even small shipments can pose health and safety risks. Under the new guidance, de minimis shipments can still be processed through Entry Type 86, but PGA data must be declared—opening up the shipment for PGA review.  

This will have a potentially significant impact on academic medical centers and start-up biotechnology and pharmaceutical companies performing basic research or proof of concept studies, where importation of small biological samples for testing must now go through the FDA review and approval process. (For more information on FDA data requirements for imports, see the FDA supplemental guide here.)

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Maria Vanikiotis Maria Vanikiotis

Maria Vanikiotis is a counsel in the International Trade Group of Crowell & Moring and resident in the firm’s New York office.

Maria has experience in a variety of matters related to the movement of goods across international borders, including problem-solving for importers

…

Maria Vanikiotis is a counsel in the International Trade Group of Crowell & Moring and resident in the firm’s New York office.

Maria has experience in a variety of matters related to the movement of goods across international borders, including problem-solving for importers facing Section 232 and Section 301 tariffs, classification of merchandise under the Harmonized Tariff Schedule, first sale appraisement programs, free trade agreement origin verifications, country of origin analyses, and other regulatory issues.

Before joining Crowell & Moring, Maria worked for a boutique law firm in New York focusing on customs law and, while in law school, Maria was employed as a summer associate in the Brussels office of a large international law firm on matters related to antitrust and competition law within the European Union. As a law student, Maria published a note comparing collective action approaches to antitrust cases in the U.S., U.K., and E.U., for which she won an award for outstanding legal writing. In addition, Maria was an active and accomplished member of both the Fordham International Law Journal and the Dispute Resolution Society.

Photo of Jason Johnson Jason Johnson

Jason Johnson is a partner in Crowell’s Health Care and Privacy & Cybersecurity Groups, where he draws on his experience as a former research scientist to advise clients on complex compliance, legal, regulatory, and transactional matters. He helps clients in the health care

…

Jason Johnson is a partner in Crowell’s Health Care and Privacy & Cybersecurity Groups, where he draws on his experience as a former research scientist to advise clients on complex compliance, legal, regulatory, and transactional matters. He helps clients in the health care and life sciences industries navigate data privacy and cybersecurity issues under U.S. and European law. He also offers strategic insights to assist clients with product development, marketing, clinical research, and other core business initiatives.

Jason is well-versed on even the most complicated regulatory challenges that his clients face. As a former research scientist in academic and pharmaceutical settings, as well as a clinical research monitor who trained physicians, Jason knows the rules firsthand. He employs this knowledge to assist clients with the full range of issues that arise in the research and development process, including drafting and negotiating research, clinical trial, licensing, and manufacturing agreements; intellectual property and technology transfer issues; collection, transfer and sharing of data, including patient registries and bio-repositories; and advising clients on mergers and acquisitions and related transactions. Jason’s clients in this area include academic medical centers, healthcare technology companies, emerging to late stage biotechnology companies, pharmaceutical and medical device companies, and other health care and research organizations.